Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment (original) (raw)
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
E. Stathopoulos
British journal of cancer, 2008
View PDFchevron_right
GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors
Kathy Vassilakos
Cancer research, 2003
View PDFchevron_right
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study
Mark Kirschbaum
Leukemia & lymphoma, 2016
View PDFchevron_right
GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors
Kathy Vassilakos
International journal of oncology, 2006
View PDFchevron_right
Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real-time reverse transcription-PCR vs. Relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products
Alice Chiu
Journal of Clinical Laboratory Analysis, 2003
View PDFchevron_right
A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors
wang bin
PeerJ
View PDFchevron_right
Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research
Konstantine Kalogeras
Virchows Archiv, 2013
View PDFchevron_right
Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma
Côme Lepage
Journal of Gastrointestinal Oncology
View PDFchevron_right
Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients
Carlos Camps
Clinical Cancer Research, 2004
View PDFchevron_right
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer
Pascal Sève
The Lancet Oncology, 2011
View PDFchevron_right
RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy
Amadeo M Parissenti
JNCI Monographs, 2015
View PDFchevron_right
Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma
Keita Kai
International journal of oncology, 2010
View PDFchevron_right
Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer
Florian Noguier
Cancers
View PDFchevron_right
Obvious and Hidden Reasons of Breast Cancer Cell Sensitivity to Antitumor RNase
Azat Garipov
BioNanoScience, 2016
View PDFchevron_right
Data from Ribonucleotide Reductase Large Subunit (<i>RRM1</i>) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer
Alfredo Berruti
2023
View PDFchevron_right
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
Kirsten Nielsen
BMC Cancer, 2013
View PDFchevron_right
Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy
Laura Pritzker
Breast Cancer Research and Treatment, 2015
View PDFchevron_right
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms
Judith Karp
Haematologica, 2013
View PDFchevron_right
Transcriptional targeting of gene expression in breast cancer by the promoters of protein regulator of cytokinesis 1 and ribonuclease reductase 2
Youngil LEE
Experimental and Molecular Medicine, 2008
View PDFchevron_right
Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients
Jacqueline Lehmann-Che
BMC Cancer, 2011
View PDFchevron_right
Detection of Tumor Cell-Specific mRNA in the Peripheral Blood of Patients with Breast Cancer—Evaluation of Several Markers with Real-Time Reverse Transcription-PCR
Klaus Friese, Matthias Ilmer
International Journal of Molecular Sciences, 2013
View PDFchevron_right
Nonisotopic Quantitation of mRNA Using a Novel RNase Protection Assay: Measurement of erbB-2 mRNA in Tumor Cell Lines
Kilian Dill
Analytical Biochemistry, 1996
View PDFchevron_right
Report from the First Meeting of the ‘European Network on Translational Research in Lung Cancer Amsterdam–Barcelona–Bialystok–Heidelberg’
Thomas Muley
Lung Cancer, 2002
View PDFchevron_right
Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance
Swati Sharma
Lung Cancer, 2005
View PDFchevron_right
Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer
Cary Grant
Clinical Cancer Research, 2008
View PDFchevron_right
A review of Ribonucleotide reductase and cancer therapies
Nur Rawaidah Shobri
2017
View PDFchevron_right
Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Pedro Fernandes
Recent Patents on Anti-Cancer Drug Discovery, 2007
View PDFchevron_right
Gene Section Atlas of Genetics and Cytogenetics in Oncology and Haematology INIST-CNRS OPEN ACCESS JOURNAL RRM2 (ribonucleotide reductase M2)
Hamid Fiuji
View PDFchevron_right
Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer
Yukio Homma
Histopathology, 2010
View PDFchevron_right
Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer
Masanori Tsujie
International Journal of Cancer, 2007
View PDFchevron_right
Ribonucleotide Reductase Large Subunit (RRM1) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer
Ida Rapa
Clinical Cancer Research, 2012
View PDFchevron_right